Lukasz P. Gondek

Outcome heterogeneity in CALR ‐mutated myeloproliferative neoplasms

Summary Calreticulin gene ( CALR ) mutations are seen in 25%–30% of myeloproliferative neoplasms (MPNs). We report outcomes and high‐risk genomic signatures in 149 patients with CALR‐mutated MPN. CALR‐mutated essential thrombocythaemia ( n = 106) progressed to myelofibrosis ( n =...